PTEN Is Involved in Sunitinib and Sorafenib Resistance in Renal Cell Carcinoma. 2020

Yohei Sekino, and Takeshi Hagura, and Xiangrui Han, and Takashi Babasaki, and Keisuke Goto, and Shogo Inoue, and Tetsutaro Hayashi, and Jun Teishima, and Masanobu Shigeta, and Daiki Taniyama, and Kazuya Kuraoka, and Kazuhiro Sentani, and Wataru Yasui, and Akio Matsubara
Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan akikosekino@gmail.com.

OBJECTIVE Targeted receptor tyrosine kinase inhibitor (TKI) is a standard treatment in advanced renal cell carcinoma (RCC). However, the role of PTEN in TKI resistance remains poorly understood. We aimed to determine the functional role of PTEN knockout and analyse the predictive significance of PTEN expression for TKI treatment in RCC. METHODS We developed PTEN knockout cells in RCC cell lines using the CRISPR-Cas9 system and analysed the effect of PTEN knockout on spheroid formation and resistance to sunitinib and sorafenib. RESULTS PTEN knockout promoted spheroid formation and decreased sunitinib/sorafenib sensitivity in RCC cell lines. PTEN immunohistochemistry in 74 metastatic RCCs treated with sunitinib and sorafenib revealed negative PTEN expression in 23% of samples. Kaplan-Meier analysis showed a significant association of negative PTEN expression with poor progression-free survival in metastatic RCC treated with sunitinib and sorafenib (p=0.024) or sunitinib alone (p=0.009). CONCLUSIONS PTEN may be a biomarker and therapeutic target in patients with metastatic RCC.

UI MeSH Term Description Entries
D008297 Male Males
D002292 Carcinoma, Renal Cell A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma. Adenocarcinoma, Renal Cell,Carcinoma, Hypernephroid,Grawitz Tumor,Hypernephroma,Renal Carcinoma,Adenocarcinoma Of Kidney,Adenocarcinoma, Renal,Chromophil Renal Cell Carcinoma,Chromophobe Renal Cell Carcinoma,Clear Cell Renal Carcinoma,Clear Cell Renal Cell Carcinoma,Collecting Duct Carcinoma,Collecting Duct Carcinoma (Kidney),Collecting Duct Carcinoma of the Kidney,Nephroid Carcinoma,Papillary Renal Cell Carcinoma,Renal Cell Cancer,Renal Cell Carcinoma,Renal Cell Carcinoma, Papillary,Renal Collecting Duct Carcinoma,Sarcomatoid Renal Cell Carcinoma,Adenocarcinoma Of Kidneys,Adenocarcinomas, Renal Cell,Cancer, Renal Cell,Carcinoma, Collecting Duct,Carcinoma, Collecting Duct (Kidney),Carcinoma, Nephroid,Carcinoma, Renal,Carcinomas, Collecting Duct,Carcinomas, Collecting Duct (Kidney),Carcinomas, Renal Cell,Collecting Duct Carcinomas,Collecting Duct Carcinomas (Kidney),Hypernephroid Carcinoma,Hypernephroid Carcinomas,Hypernephromas,Kidney, Adenocarcinoma Of,Nephroid Carcinomas,Renal Adenocarcinoma,Renal Adenocarcinomas,Renal Carcinomas,Renal Cell Adenocarcinoma,Renal Cell Adenocarcinomas,Renal Cell Cancers,Renal Cell Carcinomas,Tumor, Grawitz
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077157 Sorafenib A niacinamide and phenylurea derivative that inhibits multiple intracellular and cell surface kinases thought to be involved in ANGIOGENESIS, including RAF KINASES and VEGF RECEPTORS. It is used in the treatment of advanced RENAL CELL CARCINOMA and HEPATOCELLULAR CARCINOMA, and for treatment of THYROID CARCINOMA refractory to radioactive iodine therapy. 4-(4-(3-(4-Chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxylic acid methyamide-4-methylbenzenesulfonate,BAY 43-9006,BAY 545-9085,BAY-545-9085,BAY-673472,Nexavar,Sorafenib N-Oxide,Sorafenib Tosylate,BAY 43 9006,BAY 439006,BAY 545 9085,BAY 5459085,BAY 673472,BAY5459085,Sorafenib N Oxide
D000077210 Sunitinib An indole and pyrrole derivative that inhibits VEGFR-2 and PDGFR BETA RECEPTOR TYROSINE KINASES. It is used as an antineoplastic agent for the treatment of GASTROINTESTINAL STROMAL TUMORS, and for treatment of advanced or metastatic RENAL CELL CARCINOMA. 5-(5-Fluoro-2-oxo-1,2-dihydroindolylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide,SU 011248,SU 11248,SU-011248,SU-11248,SU011248,SU11248,Sunitinib Malate,Sutent
D000077982 Progression-Free Survival Length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but the disease does not get worse. Event-Free Survival,Event Free Survival,Progression Free Survival,Survival, Event-Free,Survival, Progression-Free
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D015972 Gene Expression Regulation, Neoplastic Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue. Neoplastic Gene Expression Regulation,Regulation of Gene Expression, Neoplastic,Regulation, Gene Expression, Neoplastic
D047428 Protein Kinase Inhibitors Agents that inhibit PROTEIN KINASES. Protein Kinase Inhibitor,Inhibitor, Protein Kinase,Inhibitors, Protein Kinase,Kinase Inhibitor, Protein,Kinase Inhibitors, Protein

Related Publications

Yohei Sekino, and Takeshi Hagura, and Xiangrui Han, and Takashi Babasaki, and Keisuke Goto, and Shogo Inoue, and Tetsutaro Hayashi, and Jun Teishima, and Masanobu Shigeta, and Daiki Taniyama, and Kazuya Kuraoka, and Kazuhiro Sentani, and Wataru Yasui, and Akio Matsubara
July 2009, The Journal of urology,
Yohei Sekino, and Takeshi Hagura, and Xiangrui Han, and Takashi Babasaki, and Keisuke Goto, and Shogo Inoue, and Tetsutaro Hayashi, and Jun Teishima, and Masanobu Shigeta, and Daiki Taniyama, and Kazuya Kuraoka, and Kazuhiro Sentani, and Wataru Yasui, and Akio Matsubara
October 2021, Anticancer research,
Yohei Sekino, and Takeshi Hagura, and Xiangrui Han, and Takashi Babasaki, and Keisuke Goto, and Shogo Inoue, and Tetsutaro Hayashi, and Jun Teishima, and Masanobu Shigeta, and Daiki Taniyama, and Kazuya Kuraoka, and Kazuhiro Sentani, and Wataru Yasui, and Akio Matsubara
September 2021, Anticancer research,
Yohei Sekino, and Takeshi Hagura, and Xiangrui Han, and Takashi Babasaki, and Keisuke Goto, and Shogo Inoue, and Tetsutaro Hayashi, and Jun Teishima, and Masanobu Shigeta, and Daiki Taniyama, and Kazuya Kuraoka, and Kazuhiro Sentani, and Wataru Yasui, and Akio Matsubara
January 2019, Oncology,
Yohei Sekino, and Takeshi Hagura, and Xiangrui Han, and Takashi Babasaki, and Keisuke Goto, and Shogo Inoue, and Tetsutaro Hayashi, and Jun Teishima, and Masanobu Shigeta, and Daiki Taniyama, and Kazuya Kuraoka, and Kazuhiro Sentani, and Wataru Yasui, and Akio Matsubara
January 2009, Cancer,
Yohei Sekino, and Takeshi Hagura, and Xiangrui Han, and Takashi Babasaki, and Keisuke Goto, and Shogo Inoue, and Tetsutaro Hayashi, and Jun Teishima, and Masanobu Shigeta, and Daiki Taniyama, and Kazuya Kuraoka, and Kazuhiro Sentani, and Wataru Yasui, and Akio Matsubara
July 2007, Clinical cancer research : an official journal of the American Association for Cancer Research,
Yohei Sekino, and Takeshi Hagura, and Xiangrui Han, and Takashi Babasaki, and Keisuke Goto, and Shogo Inoue, and Tetsutaro Hayashi, and Jun Teishima, and Masanobu Shigeta, and Daiki Taniyama, and Kazuya Kuraoka, and Kazuhiro Sentani, and Wataru Yasui, and Akio Matsubara
January 2014, Journal of kidney cancer and VHL,
Yohei Sekino, and Takeshi Hagura, and Xiangrui Han, and Takashi Babasaki, and Keisuke Goto, and Shogo Inoue, and Tetsutaro Hayashi, and Jun Teishima, and Masanobu Shigeta, and Daiki Taniyama, and Kazuya Kuraoka, and Kazuhiro Sentani, and Wataru Yasui, and Akio Matsubara
August 2010, Annals of oncology : official journal of the European Society for Medical Oncology,
Yohei Sekino, and Takeshi Hagura, and Xiangrui Han, and Takashi Babasaki, and Keisuke Goto, and Shogo Inoue, and Tetsutaro Hayashi, and Jun Teishima, and Masanobu Shigeta, and Daiki Taniyama, and Kazuya Kuraoka, and Kazuhiro Sentani, and Wataru Yasui, and Akio Matsubara
March 2022, Scientific reports,
Yohei Sekino, and Takeshi Hagura, and Xiangrui Han, and Takashi Babasaki, and Keisuke Goto, and Shogo Inoue, and Tetsutaro Hayashi, and Jun Teishima, and Masanobu Shigeta, and Daiki Taniyama, and Kazuya Kuraoka, and Kazuhiro Sentani, and Wataru Yasui, and Akio Matsubara
July 2013, Journal of geriatric oncology,
Copied contents to your clipboard!